GlassScriptPhysician profile
Christopher M Dente
NPI 1770598401
$7,523.62
in general payments reported to CMS, 2019-2025
14 companies · $798 in 2025
The $798 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,086 · 2020: $783 · 2021: $499 · 2022: $549 · 2023: $325 · 2024: $484 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,645.56 | 2019-2022 | |
| Sight Sciences, INC. | $507.86 | 2019-2023 | Omni Surgical System |
| Abbvie INC. | $429.81 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Glaukos Corporation | $407.42 | 2024-2025 | Idose |
| Eyevance Pharmaceuticals LLC | $399.68 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $374.73 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $231.71 | 2019-2023 | |
| Alcon Vision LLC | $212.54 | 2019-2025 | Tryptyr |
| Johnson & Johnson Vision Care, INC. | $143.25 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $52.08 | 2019-2021 | |
| Oyster Point Pharma, INC. | $44.67 | 2022-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $32.90 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.19 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.